Croma-Pharma boosts market share & cataract portfolio

Article

Austrian pharmaceutical firm Croma-Pharma has acquired two companies, thus strengthening its cataract surgery portfolio and, according to the firm, moving it into the top five list of companies operating in the European ophthalmic market.

Austrian pharmaceutical firm Croma-Pharma has acquired two companies, thus strengthening its cataract surgery portfolio and, according to the firm, moving it into the top five list of companies operating in the European ophthalmic market.

Specifically, the firm has now completed the acquisitions of Cornéal Laboratoir and Xcelens.

Cornéal has a strong line of products for anterior and posterior surgery, such as viscolelastic fluids, IOLs and medical devices. Xcelens, despite only being founded in 2003, also has a reputation as a leading provider in the cataract surgery field, with its main interest lying in export.

These acquisitions have now made Croma-Pharma a one-stop provider of cataract surgery products.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.